References: Cancer incidence in Canada: trends and projections (1983-2032) - HPCDP: Volume 35, Supplement 1, Spring 2015

References

Footnote 1

Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian cancer statistics 2013. Toronto (ON): Canadian Cancer Society; 2013.

Return to footnote1 referrer

Footnote 2

National Cancer Registry. Trends in Irish cancer incidence 1994–2002 with predictions to 2020 [Internet]. Cork (IE): National Cancer Registry; 2006 [cited 2013 Oct 28].

Return to footnote2 referrer

Footnote 3

Møller B, Fekjær H, Hakulinen T, et al. Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev. 2002;Suppl 11:S1-96.

Return to footnote3 referrer

Footnote 4

Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer. 2011;105:1795-803.

Return to footnote4 referrer

Footnote 5

New Zealand: Ministry of Health. Cancer in New Zealand: trends and projections [Internet]. New Zealand: Ministry of Health; 2002 [cited 2013 Oct 28].

Return to footnote5 referrer

Footnote 6

World Health Organization. International classification of diseases, 9th revision. Volumes 1 and 2. Geneva (CH): World Health Organization; 1977.

Return to footnote6 referrer

Footnote 7

Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology, 3rd ed. Geneva (CH): World Health Organization; 2000.

Return to footnote7 referrer

Footnote 8

National Cancer Institute. SEER incidence site recode [Internet]. Bethesda (MD): National Cancer Institute; 2003 [cited 2013 Oct 28].

Return to footnote8 referrer

Footnote 9

Statistics Canada. Demographic estimates compendium 2010. Ottawa (ON): Ministry of Industry; 2010. CANSIM table 051-0001 released on September 29, 2010.

Return to footnote9 referrer

Footnote 10

Statistics Canada. Population projections for Canada, provinces and territories: 2009 to 2036 [Internet]. Ottawa: Ministry of Industry; 2010 [cited 2013 Oct 28]. [Statistics Canada, Catalogue No. 91-520-X]

Return to footnote10 referrer

Footnote 11

Breslow N, Day N. Statistical methods in cancer research. Volume 2: The design and analysis of cohort studies. Lyon (FR): IARC Scientific Publications no. 82; 1987.

Return to footnote11 referrer

Footnote 12

Hakulinen T, Dyba T. Precision of incidence predictions based on Poisson distributed observations. Stat Med. 1994;13:1513-23.

Return to footnote12 referrer

Footnote 13

Dyba T, Hakulinen T. Comparison of different approaches to incidence prediction based on simple interpolation techniques. Stat Med. 2000;19:1741-52.

Return to footnote13 referrer

Footnote 14

Holford TR. The estimation of age, period and cohort effects for vital rates. Biometrics. 1983;39:311-24.

Return to footnote14 referrer

Footnote 15

Moller B, Fekjaer H, Hakulinen T, et al. Prediction of cancer incidence in the Nordic countries: Empirical comparison of different approaches. Stat Med. 2003;22:2751-66.

Return to footnote15 referrer

Footnote 16

Osmond C. Using age, period and cohort models to estimate future mortality rates. Int J Epidemiol. 1985;14:124-9.

Return to footnote16 referrer

Footnote 17

McCullagh P, Nelder JA. Generalized linear models, 2nd ed. London (UK): Chapman and Hall; 1989.

Return to footnote17 referrer

Footnote 18

Hastie TJ, Tibshirani RJ. Generalized additive models. London (UK): Chapman and Hall; 1990.

Return to footnote18 referrer

Footnote 19

Wood SN. Generalized additive models: an introduction with R. Boca Raton (Fl): Chapman and Hall; 2006.

Return to footnote19 referrer

Footnote 20

Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med. 2002;21:3511-26.

Return to footnote20 referrer

Footnote 21

Carstensen B. Age-period-cohort models for the lexis diagram. Stat Med. 2007;26:3018- 45.

Return to footnote21 referrer

Footnote 22

Bray I. Application of Markov chain Monte Carlo methods to projecting cancer incidence and mortality. J R Stat Soc Ser C, Appl Stat. 2002;51:151-64.

Return to footnote22 referrer

Footnote 23

Robert CP, Casella G. Monte Carlo Statistical Methods. New York: Springer- Verlag; 1999.

Return to footnote23 referrer

Footnote 24

Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758-2765.

Return to footnote24 referrer

Footnote 25

Cancer Registry of Norway. Nordpred software package [software]. Oslo (NO): Institute of Population-Based Research; 2009 [cited 2013 Oct 28].

Return to footnote25 referrer

Footnote 26

Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med. 1987;6:469-81.

Return to footnote26 referrer

Footnote 27

Lee TC, Dean CB, Semenciw R. Short-term cancer mortality projections: a comparative study of prediction methods. Stat Med. 2011;30:3387-402.

Return to footnote27 referrer

Footnote 28

Moller H, Fairley L, Coupland V, et al. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer. 2007;96:1484-8.

Return to footnote28 referrer

Footnote 29

Coupland VH, Okello C, Davies EA, Bray F, Møller H. The future burden of cancer in London compared with England. J Public Health (Oxf). 2010;32:83-9.

Return to footnote29 referrer

Footnote 30

Aitken R, Morell S, Barraclough H, et al. Cancer incidence and mortality projections in New South Wales, 2007 to 2011. New South Wales: Cancer Institute; 2008.

Return to footnote30 referrer

Footnote 31

Olsen AH, Parkin DM, Sasieni P. Cancer mortality in the United Kingdom: Projections to the year 2025. Br J Cancer. 2008;99:1549- 54.

Return to footnote31 referrer

Footnote 32

Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing. 2000;10:325-37.

Return to footnote32 referrer

Footnote 33

Ntzoufras I. Bayesian Modeling Using WinBUGS. Hoboken, New Jersey (NY): John Wiley & Sons; 2009.

Return to footnote33 referrer

Footnote 34

Spiegelhalter DJ, Thomas A, Best NG, Lunn D. BUGS Examples Volume 2 [Internet]. Cambridge (UK): The BUGS Project; 1996 [cited 2013 Oct 28].

Return to footnote34 referrer

Footnote 35

Cancer Registry of Norway. Cancer in Norway 2005—Special issue: Predictions of cancer incidence by health region 2010–2020 [Internet]. Oslo (NO): Cancer Registry of Norway; 2012 [cited 2013 Oct 28].

Return to footnote35 referrer

Footnote 36

Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian cancer statistics 2011. Toronto (ON): Canadian Cancer Society; 2011.

Return to footnote36 referrer

Footnote 37

Band PR, Gaudette LA, Hill GB, et al. The making of the Canadian Cancer Registry: cancer incidence in Canada and its regions, 1969 to 1988. Ottawa: Minister of Supply and Services; 1993.

Return to footnote37 referrer

Footnote 38

Pelletier G. La survie reliéé au cancer. Étude des nouveau cas de cancer déclarés au Québec au cours des années 1984, 1985, et 1986. Collection Données statistiques et Indicateurs. Quebec: Government of Quebec, Ministry of Health and Social Services, Planning and Evaluation Branch; 1993.

Return to footnote38 referrer

Footnote 39

Larsen RJ, Marx ML. An introduction to mathematical statistics and its applications, 3rd ed. Upper Saddle River (NJ): Prentice Hall; 2001.

Return to footnote39 referrer

Footnote 40

Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-51.

Return to footnote40 referrer

Footnote 41

National Cancer Institute. Joinpoint regression program [Internet software]. Bethesda (MD): National Cancer Institute; 2013 [updated 2013 May 6; cited 2013 Oct 30].

Return to footnote41 referrer

Footnote 42

National Cancer Institute of Canada. Canadian cancer statistics 2000. Toronto (ON): Canadian Cancer Society; 2000.

Return to footnote42 referrer

Footnote 43

Health Canada. Canadian Tobacco Use Monitoring Survey (CTUMS) 2011 [Internet]. Ottawa (ON): Health Canada; 2011 [cited 2013 Sept 4].

Return to footnote43 referrer

Footnote 44

Weiss W. Cigarette smoking and lung cancer trends. A light at the end of the tunnel? Chest. 1997;111:1414-6.

Return to footnote44 referrer

Footnote 45

Canadian Partnership Against Cancer. Cervical cancer screening in Canada: programs and strategies [Internet]. Toronto (ON): Canadian Partnership Against Cancer; 2013 [updated 2013 Mar; cited 2013 Oct 28].

Return to footnote45 referrer

Footnote 46

Canadian Partnership Against Cancer. Cervical cancer control in Canada [Internet]. Toronto (ON): Canadian Partnership Against Cancer; 2013 [updated 2012 Aug 20; cited 2013 Oct 28].

Return to footnote46 referrer

Footnote 47

International Agency for Research on Cancer. Agents classified by the IARC monographs, Volumes 1-109 IARC Monographs on the evaluation of carcinogenic risks to humans [Internet]. Lyon (FR): International Agency for Research on Cancer; 2013 [updated 2013 Oct 30; cited 2013 Dec 21].

Return to footnote47 referrer

Footnote 48

Turati F, Garavello W, Tramacere I, et al. A meta-analysis of alcohol drinking and oral and pharyngeal cancers: results from subgroup analyses. Alcohol Alcohol. 2013;48:107-18.

Return to footnote48 referrer

Footnote 49

Gandini S, Botteri E, Iodice S, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122:155-64.

Return to footnote49 referrer

Footnote 50

Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer. 2001;85:1700-5.

Return to footnote50 referrer

Footnote 51

Statistics Canada. Health trends 2013 [Internet]. Ottawa (ON): Statistics Canada; 2013 [cited 2013 Oct 28]. [Statistics Canada Catalogue No. 82-213-XWE].

Return to footnote51 referrer

Footnote 52

Kufe DW, Bast Jr RC, Hait WN, et al. Cancer medicine, 7th ed. Hamilton (ON): BC Decker Inc.; 2006.

Return to footnote52 referrer

Footnote 53

Haskell CM. Cancer treatment, 5th ed. Philadelphia (PA): WB Saunders Company; 2001.

Return to footnote53 referrer

Footnote 54

Forte T, Niu J, Lockwood GA, Bryant HE. Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992-2009. Cancer Causes Control. 2012;23(8):1343-8.

Return to footnote54 referrer

Footnote 55

Johnson-Obaseki S, McDonald JT, Corsten M, Rourke R. Head and neck cancer in Canada: trends 1992 to 2007. Otolaryngol Head Neck Surg. 2012;147(1):74-8.

Return to footnote55 referrer

Footnote 56

Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175-201.

Return to footnote56 referrer

Footnote 57

Blomberg M, Nielsen A, Munk C, Kjaer SK. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer. 2011;129(3):733-41.

Return to footnote57 referrer

Footnote 58

Shin A, Jung YS, Jung KW, Kim K, Ryu J, Won YJ. Trends of human papilloma virus related head and neck cancers in Korea: National cancer registry data. Laryngoscope. 2013 Nov;123(11):E30-7.

Return to footnote58 referrer

Footnote 59

National Advisory Committee on Immunization (NACI). Update on human papillomavirus (HPV) vaccines. An Advisory Committee Statement (ACS). CCDR. 2012:38 (ACS-1). Ottawa (ON): Public Health Agency of Canada; [updated 2012 Aug 27; cited 2013 Dec 21].

Return to footnote59 referrer

Footnote 60

Wilson SE, Harris T, Sethi P, Fediurek J, Macdonald L, Deeks SL. Coverage from Ontario, Canada's school-based HPV vaccine program: the first three years. Vaccine. 2013;31(5):757-62.

Return to footnote60 referrer

Footnote 61

Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian cancer statistics 2010. Toronto (ON): Canadian Cancer Society; 2010.

Return to footnote61 referrer

Footnote 62

Lagergren J. Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis? Best Pract Res Clin Gastroenterol. 2006;20:803-12.

Return to footnote62 referrer

Footnote 63

Blot WJ, McLaughlin JK, Fraumeni JF Jr. Esophageal cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention, 3rd ed. New York (NY): Oxford University Press; 2006. p. 697-706.

Return to footnote63 referrer

Footnote 64

Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012; 23:3155-62.

Return to footnote64 referrer

Footnote 65

Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 2007;165:1424- 33.

Return to footnote65 referrer

Footnote 66

Lee YC,MarronM, Benhamou S, et al. Active and involuntary tobacco smoking and upper aerodigestive tract cancer risks in a multicenter case-control study. Cancer Epidemiol Biomarkers Prev. 2009;18:3353-61.

Return to footnote66 referrer

Footnote 67

Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404-13.

Return to footnote67 referrer

Footnote 68

Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232-48.

Return to footnote68 referrer

Footnote 69

Fedorak RN, van Zanten SV, Bridges R. Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol. 2010;24:431-4.

Return to footnote69 referrer

Footnote 70

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-78.

Return to footnote70 referrer

Footnote 71

Steffen A, Schulze MB, Pischon T, et al. Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2009;18:2079-89.

Return to footnote71 referrer

Footnote 72

Tjepkema, M. Adult obesity in Canada: measured height and weight. In: Nutrition: findings from the Canadian Community Health Survey, no. 1. [Statistics Canada Catalogue No. 82-620-MWE]. Ottawa (ON): Statistics Canada; 2006.

Return to footnote72 referrer

Footnote 73

Public Health Agency of Canada. Obesity in Canada [Internet]. Ottawa (ON): Public Health Agency of Canada; 2011[updated 2011 Jun 23; cited 2013 Oct 28].

Return to footnote73 referrer

Footnote 74

El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17-26.

Return to footnote74 referrer

Footnote 75

Statistics Canada. Population by selected ethnic origins, by province and territory (2006 Census). [Internet]. Ottawa (ON): Statistics Canada [updated 2009 Jul 28; cited 2009 Jul 28].

Return to footnote75 referrer

Footnote 76

World Health Organization. Hepatitis B. Fact sheet no. 204 [Internet]. Geneva (CH): World Health Organization; 2013 [updated 2013 Jul; cited 2013 Oct 28].

Return to footnote76 referrer

Footnote 77

Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212-9.

Return to footnote77 referrer

Footnote 78

Burak KW, Coffin CS, Myers RP. Hepatitis B awareness and education: a failing grade. Can J Gastroenterol. 2011;25:125-6.

Return to footnote78 referrer

Footnote 79

Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012;4(7):156-69.

Return to footnote79 referrer

Footnote 80

D'Elia L, Rossi G, Ippolito R, Cappuccio FP, Strazzullo P. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr. 2012;31(4):489-98.

Return to footnote80 referrer

Footnote 81

Statistics Canada. Food statistics 2009. Ottawa (ON): Statistics Canada; 2009 [cited 2013 Oct 28]. [Statistics Canada, Catalogue No. 21-020-XWE]. Available from:

Return to footnote81 referrer

Footnote 82

Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev. 1986;8:1-27.

Return to footnote82 referrer

Footnote 83

International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 61. Lyon (FR): IARC Press; 1994.

Return to footnote83 referrer

Footnote 84

Public Health Agency of Canada. Colorectal cancer [Internet]. Ottawa (ON): Public Health Agency of Canada; 2013 [updated 2013 Apr 22; cited 2013 Oct 28]. Available from:

Return to footnote84 referrer

Footnote 85

Cancer Research UK. Bowel cancer risk factors [Internet]. London (UK): Cancer Research UK; 2012 [updated 2012 Jan 31; cited 2013 Oct 28].

Return to footnote85 referrer

Footnote 86

Boyle P, Levin B, editors. World Cancer report 2008 [Internet]. Lyon (FR): International Agency for Research on Cancer; 2008 [cited 2013 Oct 28].

Return to footnote86 referrer

Footnote 87

Aune D, Lau R, Chan DS, et al. Nonlinear reduction in risk for colorectal cancer by fruit and vegetable intake based on meta-analysis of prospective studies. Gastroenterology. 2011;141:106-18.

Return to footnote87 referrer

Footnote 88

Labonte R, Muhajarine N, Winquist B, Quail J. Healthy populations: a report of the Canadian index of wellbeing (CIW) [Internet]. Waterloo (ON): Waterloo University; September 2010 [cited 2013 Oct 28].

Return to footnote88 referrer

Footnote 89

Lin KJ, Cheug WY, Lai JY, Giovannucci EL. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer. 2012;130:419-30.

Return to footnote89 referrer

Footnote 90

Garriguet D. Canadians' eating habits. Health Rep. 2007;18:17-32.

Return to footnote90 referrer

Footnote 91

Nesbitt A, Majowicz S, Finley R. Food consumption patterns in the Waterloo Region, Ontario, Canada: a cross-sectional telephone survey. BMC Public Health. 2008;8:370.

Return to footnote91 referrer

Footnote 92

Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573.

Return to footnote92 referrer

Footnote 93

Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120;1290-314.

Return to footnote93 referrer

Footnote 94

Canadian Partnership Against Cancer. Colorectal cancer screening - 2010 [Internet]. Toronto (ON): Canadian Partnership Against Cancer; 2010 [cited 2013 Dec 21].

Return to footnote94 referrer

Footnote 95

Kadiyala S, Strumpf EC. Are United States and Canadian cancer screening rates consistent with guideline information regarding the age of screening initiation? Int J Qual Health Care. 2011;23:611-20.

Return to footnote95 referrer

Footnote 96

El-Seraq HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-27.

Return to footnote96 referrer

Footnote 97

Yang JD, Kim B, Sanderson SO, et al. Hepatocellular carcinoma in Olmsted County, Minnesota, 1976-2008. Mayo Clin Proc. 2012;87:9-16.

Return to footnote97 referrer

Footnote 98

Dyer Z, Peltekian K, van Zanten SV. Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther. 2005;22:17-22.

Return to footnote98 referrer

Footnote 99

Public Health Agency of Canada. Hepatitis C in Canada: 2005-2010 surveillance report [Internet]. Ottawa (ON): Public Health Agency of Canada; 2012 [cited 2013 Dec 21].

Return to footnote99 referrer

Footnote 100

Bosch FX, Rives J, Diaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastrenterology. 2004;127:S7-16.

Return to footnote100 referrer

Footnote 101

Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol. 2000;14:575-80.

Return to footnote101 referrer

Footnote 102

Public Health Agency of Canada. National immunization strategy: final report 2003. Ottawa (ON): Public Health Agency of Canada; 2004 [updated 2004 Jun 16; cited 2013 Oct 28].

Return to footnote102 referrer

Footnote 103

Public Health Agency of Canada. Vaccine-preventable diseases [Internet]. Ottawa (ON): Public Health Agency of Canada; 2012 [updated 2012 Jul 20; cited 2013 Oct 28].

Return to footnote103 referrer

Footnote 104

McDermott S, DesMeules M, Lewis R, et al. Cancer incidence among Canadian immigrants, 1980-1998: results from a national cohort study. J Immigr Minor Health. 2011;13:15-26.

Return to footnote104 referrer

Footnote 105

Statistics Canada. Immigrant population by place of birth, by province and territory (2006 Census) [Internet]. Ottawa (ON): Statistics Canada; 2007 [updated 2007 Dec 11; cited 2013 Oct 28].

Return to footnote105 referrer

Footnote 106

Statistics Canada. Selected trend data for Canada, 1996, 2001 and 2006 censuses [Internet]. Ottawa (ON): Statistics Canada; 2010 [updated 2010 Feb 6; cited 2013 Oct 28].

Return to footnote106 referrer

Footnote 107

Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S206-14.

Return to footnote107 referrer

Footnote 108

Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:2338-66.

Return to footnote108 referrer

Footnote 109

Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-6.

Return to footnote109 referrer

Footnote 110

Shields M, Tremblay MS, Laviolette M, Craig CL, Janssen I, Connor Gorber S. Fitness of Canadian adults: results from the 2007-2009 Canadian Health Measures Survey. Health Rep. 2010;21:21-35.

Return to footnote110 referrer

Footnote 111

Devita VT Jr, Hellman S, Rosenberg SA. Cancer: principles & practice of oncology, 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005.

Return to footnote111 referrer

Footnote 112

Villeneuve PJ, Johnson KC, Mao Y, Hanley AJ. Environmental tobacco smoke and the risk of pancreatic cancer: findings from a Canadian population-based case-control study. Can J Public Health. 2004;95:32-7.

Return to footnote112 referrer

Footnote 113

Gallicchio L, Kouzis A, Genkinger J, et al. Active cigarette smoking, household passive smoke exposure, and the risk of developing pancreatic cancer. Prev Med. 2006;42:200-5.

Return to footnote113 referrer

Footnote 114

Weiss W, Benarde MA. The temporal relation between cigarette smoking and pancreatic cancer. Am J Public Health. 1983;73:1403-4.

Return to footnote114 referrer

Footnote 115

Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer. 1999;80:1830-7.

Return to footnote115 referrer

Footnote 116

Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev. 2003;27:87- 93.

Return to footnote116 referrer

Footnote 117

World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project: keeping the science current. Pancreatic cancer 2012 report: food, nutrition, physical activity, and the prevention of pancreatic cancer [Internet]. World Cancer Research Fund; 2012 [cited 2013 Dec 21].

Return to footnote117 referrer

Footnote 118

Bao Y, Michaud DS, Spiegelman D. Folate intake and risk of pancreatic cancer: pooled analysis of prospective cohort studies. J Natl Cancer Inst. 2011;103:1840-50.

Return to footnote118 referrer

Footnote 119

Aune D, Greenwood DC, Chan DS, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23:843-52.

Return to footnote119 referrer

Footnote 120

O'Rorke M, Cantwell MM, Cardwell CR, Mulholland HG, Murray LJ. Can physical activity modulate pancreatic cancer risk? a systematic review and meta-analysis. Int J Cancer. 2010;126:2957-68.

Return to footnote120 referrer

Footnote 121

Bao Y, Michaud DS. Physical activity and pancreatic cancer risk: a systematic review. Cancer Epidemiol Biomarkers Prev. 2008;17:2671-82.

Return to footnote121 referrer

Footnote 122

Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer. 2011;47:1928-37.

Return to footnote122 referrer

Footnote 123

Elena JW, Steplowski E, Yu K, et al. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control. 2013;24:13-25.

Return to footnote123 referrer

Footnote 124

Cancer Research UK. Pancreatic cancer incidence statistics [Internet]. London (UK): Cancer Research UK; 2013 [updated 2013 Oct 18; cited 2013 Oct 28].

Return to footnote124 referrer

Footnote 125

Berrino F, Crosignani P. [Epidemiology of malignant tumors of the larynx and lung]. Ann Ist Super Sanita. 1992;28:107-20.

Return to footnote125 referrer

Footnote 126

Burch JD, Howe GR, Miller AB, Semenciw R. Tobacco, alcohol, asbestos, and nickel in the etiology of cancer of the larynx: a casecontrol study. J Natl Cancer Inst. 1981;67: 1219-24.

Return to footnote126 referrer

Footnote 127

Health Canada. Canadian Alcohol and Drug Use Monitoring Survey: summary of results for 2011. Ottawa (ON): Health Canada; 2012 [updated 2012 Jul 03; cited 2013 Oct 28].

Return to footnote127 referrer

Footnote 128

Surgeon General. Reducing the health consequences of smoking: 25 years of progress. Washington (DC): U.S. Department of Health and Human Services, Centers for Disease Control; 1989.

Return to footnote128 referrer

Footnote 129

Shopland DR. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect. 1995;103:131-42.

Return to footnote129 referrer

Footnote 130

Brisson J, Major D, Pelletier E. Évaluation de l'exhaustivité du fichier des tumeurs du Québec. Québec (QC): Institut national de la santé publique du Québec; 2003.

Return to footnote130 referrer

Footnote 131

Sneyd M, Cox B. The control of melanoma in New Zealand. N Z Med J. 2006;119:U2169.

Return to footnote131 referrer

Footnote 132

Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41:45-60.

Return to footnote132 referrer

Footnote 133

Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer. 1997;73:198-203.

Return to footnote133 referrer

Footnote 134

Miller AJ, Mihm MC, Jr. Melanoma. N Engl J Med. 2006;355:51-65.

Return to footnote134 referrer

Footnote 135

Naldi L, Randi G, Di Landro A, La Vecchia C. Red hHairs, number of nevi, and risk of cutaneous malignant melonoma: results from a case-control study in Italy. Arch Dermatol. 2006;142:935-6.

Return to footnote135 referrer

Footnote 136

Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling. Int J Cancer. 2010;127:2430-45.

Return to footnote136 referrer

Footnote 137

Williams PF, Olsen CM, Hayward NK, Whiteman DC. Melanocortin 1 receptor and risk of cutaneous melanoma: a metaanalysis and estimates of population burden. Int J Cancer. 2011;129:1730-40.

Return to footnote137 referrer

Footnote 138

Olsen CM, Carroll HJ, Whiteman DC. Familial melanoma: a meta-analysis and estimates of attributable fraction. Cancer Epidemiol Biomarkers Prev. 2010;19:65-73.

Return to footnote138 referrer

Footnote 139

Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41:2040-59.

Return to footnote139 referrer

Footnote 140

Law MH, Macgregor S, Hayward NK. Melanoma genetics: recent findings take us beyond well-traveled pathways. J Invest Dermatol. 2012;132:1763-74.

Return to footnote140 referrer

Footnote 141

Erdmann F, Lortet-Tieulent J, Schüz J, et al. International trends in the incidence of malignant melanoma 1953-2008—are recent generations at higher or lower risk? Int J Cancer. 2013;132:385-400.

Return to footnote141 referrer

Footnote 142

Shields M, Wilkins K. An update on mammography use in Canada. Health Rep. 2009;20:7-19.

Return to footnote142 referrer

Footnote 143

Canadian Task Force on Preventive Health Care. Screening for Breast Cancer - Summary of recommendations for clinicians and policy-makers [Internet]. Edmonton (AB): Canadian Task Force on Preventive Health Care; 2014 [cited 2014 Mar 28].

Return to footnote143 referrer

Footnote 144

Canadian Association of Radiologists. CAR practice guidelines and technical standards for breast imaging and intervention. Ottawa (ON): Canadian Association of Radiologists; [updated 2012 Sep 29; cited 2014 Mar 28]. Available from:

Return to footnote144 referrer

Footnote 145

Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ. 2004;328:921-4.

Return to footnote145 referrer

Footnote 146

Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348: g366.

Return to footnote146 referrer

Footnote 147

Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2:133- 40.

Return to footnote147 referrer

Footnote 148

Ford D, Nault F. Changing Fertility Patterns, 1974 to 1994. Health Reports. 1996;8:39-46.

Return to footnote148 referrer

Footnote 149

Statistics Canada. Births and total fertility rate, by province and territory (Fertility rate) [Internet]. Ottawa: Statistics Canada [updated 2013 Mar 19; cited 2013 Sept 6].

Return to footnote149 referrer

Footnote 150

Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872-81.

Return to footnote150 referrer

Footnote 151

Cancer Research UK. Breast cancer risk factors [Internet]. London (UK): Cancer Research UK [updated 2013 Dec 17; cited 2013 Dec 19]. Available from:

Return to footnote151 referrer

Footnote 152

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33.

Return to footnote152 referrer

Footnote 153

De P, Neutel CI, Olivotto I, Morrison H. Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst. 2010;102(19):1489-95.

Return to footnote153 referrer

Footnote 154

Boyd NF, Martin LJ, Sun L et al. Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:2086-92.

Return to footnote154 referrer

Footnote 155

Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res. 2011;13:223.

Return to footnote155 referrer

Footnote 156

Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M. A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1048-53.

Return to footnote156 referrer

Footnote 157

Huo CW, Chew GL, Britt KL, et al. Mammographic density-a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat. 2014;144:479-502.

Return to footnote157 referrer

Footnote 158

Bertrand KA, Tamimi RM, Scott CG, et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res. 2013;15:R104.

Return to footnote158 referrer

Footnote 159

Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Summary and conclusions. Br J Cancer. 2011;105:S77-81.

Return to footnote159 referrer

Footnote 160

Monninkhof EM, Elias SG, Vlems FA. Physical activity and breast cancer: a systematic review. Epidemiology. 2007;18:137- 157.

Return to footnote160 referrer

Footnote 161

Kobayashi LC, Janssen I, Richardson H, Lai AS, Spinelli JJ, Aronson KJ. A case-control study of lifetime light intensity physical activity and breast cancer risk. Cancer Causes Control. 2014;25(1):133-40.

Return to footnote161 referrer

Footnote 162

Baan R, Straif K, Grosse Y, et al. WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007; 8:292-3.

Return to footnote162 referrer

Footnote 163

Cogliano VJ, Baan R, Straif K, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103:1827-39.

Return to footnote163 referrer

Footnote 164

Reynolds P. Smoking and breast cancer. J Mammary Gland Biol Neoplasia. 2013;18:15- 23.

Return to footnote164 referrer

Footnote 165

Johnson KC, Miller AB, Collishaw NE, et al. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). Tob Control. 2011;20:e2.

Return to footnote165 referrer

Footnote 166

Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9.

Return to footnote166 referrer

Footnote 167

Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 2002;3:11-6.

Return to footnote167 referrer

Footnote 168

Deneris A, Bond S. Clinical update: human papillomavirus vaccine. J Midwifery Womens Health. 2006;51:515-8.

Return to footnote168 referrer

Footnote 169

Moore RA, Ogilvie G, Fornika D, et al. Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women–implications for vaccination. Cancer Causes Control. 2009;20:1387-96.

Return to footnote169 referrer

Footnote 170

Palefsky JM, Holly EA. Chapter 6: Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr. 2003;31:41- 46.

Return to footnote170 referrer

Footnote 171

Parkin DM. Tobacco-attributable cancer burden in the UK in 2010. Br J Cancer. 2011;105:S6-13.

Return to footnote171 referrer

Footnote 172

Colucci R, Hryniuk W, Savage C. HPV vaccination programs in Canada: are we hitting the mark? In: Cancer Advocacy Coalition of Canada. Report card on cancer in Canada, 2008 [Internet]. Cancer Advocacy Coalition of Canada; 2008 [cited 2013 Sept 6].

Return to footnote172 referrer

Footnote 173

Public Health Agency of Canada. Human papillomavirus (HPV) prevention and HPV vaccines: questions and answers [Internet]. Ottawa (ON): Public Health Agency of Canada; 2011 [updated 2011 Mar 31; cited 2013 Sept 6]. Available from:

Return to footnote173 referrer

Footnote 174

Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005;6:552-3.

Return to footnote174 referrer

Footnote 175

Cust AE, Armstrong BK, Friedenreich CM, Slimani N, Bauman A. Physical activity and endometrial cancer risk: a review of the current evidence, biologic mechanisms and the quality of physical activity assessment methods. Cancer Causes Control. 2007;18: 243-58.

Return to footnote175 referrer

Footnote 176

Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial cancer risk: results from a systematic review andmeta-analysis. Int J BiolMarkers. 2014;29(1):e21-9.

Return to footnote176 referrer

Footnote 177

Arem H, Irwin ML, Zhou Y, Lu L, Risch H, Yu H. Physical activity and endometrial cancer in a population-based case-control study. Cancer Causes Control. 2011;22:219-26.

Return to footnote177 referrer

Footnote 178

Voskuil DW, Monninkhof EM, Elias SG, Vlems FA, van Leeuwen FE, Task Force Physical Activity and Cancer. Physical activity and endometrial cancer risk, a systematic reviewof current evidence. Cancer Epidemiol Biomarkers Prev. 2007;16:639-48.

Return to footnote178 referrer

Footnote 179

Bray F, dos Santos Silva I, Moller H, Weiderpasse E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev. 2005;14:1132-42.

Return to footnote179 referrer

Footnote 180

Evans T, Sany O, Pearmain P, Ganesan R, Blann A, Sundar S. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer. 2011;104:1505-10.

Return to footnote180 referrer

Footnote 181

Fisher WA, Black A. Contraception in Canada: a review of method choices, characteristics, adherence and approaches to counselling. CMAJ. 2007;176:953-61.

Return to footnote181 referrer

Footnote 182

Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European prospective investigation into cancer and nutrition. Int J Cancer. 2010;127:442-51.

Return to footnote182 referrer

Footnote 183

Tortolero-Luna G, Mitchell MF. The epidemiology of ovarian cancer. J Cell Biochem Suppl. 1995;23:200-7.

Return to footnote183 referrer

Footnote 184

Kelsey JL, Whittemore AS. Epidemiology and primary prevention of cancers of the breast, endometrium, and ovary: a brief overview. Ann Epidemiol. 1994;4:89-95.

Return to footnote184 referrer

Footnote 185

Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55:3-23.

Return to footnote185 referrer

Footnote 186

Goldman MB, Hatch M. Women and Health. Waltham (MA): Academic Press; 1999.

Return to footnote186 referrer

Footnote 187

Salehi F, Dunfield L, Phillips KP, Krewski D, Vanderhyden BC. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev. 2008;11:301-21.

Return to footnote187 referrer

Footnote 188

Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer. 2009;115:531-9.

Return to footnote188 referrer

Footnote 189

Beral V, Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369:1703-10.

Return to footnote189 referrer

Footnote 190

Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2007;96:11-5.

Return to footnote190 referrer

Footnote 191

Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev. 2010;20:231-8.

Return to footnote191 referrer

Footnote 192

Granstrom C, Sundquist J, Hemminki K. Population attributable fractions for ovarian cancer in Swedish women by morphological type. Br J Cancer. 2008;98:199-205.

Return to footnote192 referrer

Footnote 193

Negri E, Pelucchi C, Franceschi S, et al. Family history of cancer and risk of ovarian cancer. Eur J Cancer. 2003;39:505-10.

Return to footnote193 referrer

Footnote 194

Secretan B, Straif K, Baan R, et al. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009;10:1033-4.

Return to footnote194 referrer

Footnote 195

Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1991 update 3. Secondary prevention of prostate cancer. CMAJ. 1991;145:413-28.

Return to footnote195 referrer

Footnote 196

Levy IG, Gibbons L, Collins JP, Perkins DG, Mao Y. Prostate cancer trends in Canada: rising incidence or increased detection? CMAJ. 1993;149:617-24.

Return to footnote196 referrer

Footnote 197

Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2006. Toronto (ON): Canadian Cancer Society; 2006.

Return to footnote197 referrer

Footnote 198

Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914-23.

Return to footnote198 referrer

Footnote 199

Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014;311:1143-9.

Return to footnote199 referrer

Footnote 200

Evans HS,Møller H. Recent trends in prostate cancer incidence and mortality in southeast England. Eur Urol. 2003;43:337-41.

Return to footnote200 referrer

Footnote 201

Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012;2012:152-6.

Return to footnote201 referrer

Footnote 202

Kicinski M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a metaanalysis. PLoS ONE. 2011;6:e27130.

Return to footnote202 referrer

Footnote 203

Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer. 2003;107:797-803.

Return to footnote203 referrer

Footnote 204

Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003;91:794.

Return to footnote204 referrer

Footnote 205

Hemminki K, Czene K. Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer. 2002;95:1346-53.

Return to footnote205 referrer

Footnote 206

Ferlay J, Shin HR, Bray F, Forman D,Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon (FR): International Agency for Research on Cancer; 2010.

Return to footnote206 referrer

Footnote 207

Parkin DM, Ferlay J, Hamdi-Cherif M, et al. Cancer in Africa: epidemiology and prevention. 1st ed. Lyon (FR): IARC Scientific Publications no.153; 2003.

Return to footnote207 referrer

Footnote 208

Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012; 30:195-200.

Return to footnote208 referrer

Footnote 209

Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol. 2012;4:1-11.

Return to footnote209 referrer

Footnote 210

Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al. Oxidative DNA damage in prostate cancer patients consuming tomato saucebased entrees as a whole-food intervention. J Natl Cancer Inst. 2001;93:1872-1879.

Return to footnote210 referrer

Footnote 211

Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. AmJ Clin Nutr. 2009;89:1155- 63.

Return to footnote211 referrer

Footnote 212

Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst. 2005;97:1768-77.

Return to footnote212 referrer

Footnote 213

Gann PH. Risk factors for prostate cancer. Rev Urol. 2002;4 Suppl 5:S3-10.

Return to footnote213 referrer

Footnote 214

McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. Trends in the incidence of testicular germ cell tumors in the United States. Cancer. 2003;97:63-70.

Return to footnote214 referrer

Footnote 215

Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Møller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer. 2006;118:3099-111.

Return to footnote215 referrer

Footnote 216

Power DA, Brown RS, Brock CS, Payne HA, Majeed A, Babb P. Trends in testicular carcinoma in England and Wales, 1971-99. BJU Int. 2001;87:361-5.

Return to footnote216 referrer

Footnote 217

Stone JM, Cruickshank DG, Sandeman TF, Matthews JP. Trebling of the incidence of testicular cancer in Victoria, Australia (1950-1985). Cancer. 1991;68:211-9.

Return to footnote217 referrer

Footnote 218

Møller H, Fairley L, Coupland V, et al. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer. 2007;96(9):1484-8.

Return to footnote218 referrer

Footnote 219

Pettersson A, Richiardi L, Nordenskjold A, et al. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. 2007;356:1835-41.

Return to footnote219 referrer

Footnote 220

Zhang Y, Graubard BI, Klebanoff MA, et al. Maternal hormone levels among populations at high and low risk of testicular germ cell cancer. Br J Cancer. 2005;92:1787-93.

Return to footnote220 referrer

Footnote 221

Sharpe RM, Skakkebaek NE. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet. 1993;341:1392-5.

Return to footnote221 referrer

Footnote 222

Skakkebaek NE, Rajpert-De Meyts E, Jørgensen N, et al. Germ cell cancer and disorders of spermatogenesis: an environmental connection? APMIS. 1998;106:3-12.

Return to footnote222 referrer

Footnote 223

Hemminki K, Chen B. Familial risks in testicular cancer as aetiological clues. Int J Androl. 2006;29:205-10.

Return to footnote223 referrer

Footnote 224

Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J. 2008;14:288-301.

Return to footnote224 referrer

Footnote 225

Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628-31.

Return to footnote225 referrer

Footnote 226

Liu S, Semenciw R, Morrison H, Schanzer D, Mao Y. Kidney cancer in Canada: the rapidly increasing incidence of adenocarcinoma in adults and seniors. Can J Public Health. 1997;88:99-104.

Return to footnote226 referrer

Footnote 227

Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev. 2002;11:171-8.

Return to footnote227 referrer

Footnote 228

Levi F, Ferlay J, Galeone C, et al. The changing patterns of kidney cancer incidence and mortality in Europe. BJU Int. 2008;101:949-58.

Return to footnote228 referrer

Footnote 229

Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245-57.

Return to footnote229 referrer

Footnote 230

Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118-28.

Return to footnote230 referrer

Footnote 231

Patard JJ. Incidental renal tumours. Curr Opin Uro. 2009;19:454-8.

Return to footnote231 referrer

Footnote 232

Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: An analysis of surveillance, epidemiology, and end results program data. J Urol. 2002;167: 57-60.

Return to footnote232 referrer

Footnote 233

Moore LE, Wilson RT, Campleman SL. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest. 2005;23:240-55.

Return to footnote233 referrer

Footnote 234

Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006;176:2353-8.

Return to footnote234 referrer

Footnote 235

Hu J, Ugnat AM. Active and passive smoking and risk of renal cell carcinoma in Canada. Eur J Cancer. 2005;41:770-8.

Return to footnote235 referrer

Footnote 236

Chow WH, Grindley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305-11.

Return to footnote236 referrer

Footnote 237

Bao C, Yang X, Xu W et al. Diabetes mellitus and incidence and mortality of kidney cancer: A meta-analysis. J Diabetes Complications. 2013;Feb 20.

Return to footnote237 referrer

Footnote 238

Bonsib SM. Renal cystic diseases and renal neoplasms: a mini-review. Clin J Am Soc Nephrol. 2009;4:1998-2007.

Return to footnote238 referrer

Footnote 239

Curado FJA, Hernandez PC, Castro RP, et al. New epidemiologic patterns and risk factors in renal cancer. Actas Urol Esp. 2009;33:459-67.

Return to footnote239 referrer

Footnote 240

Karami S, Lan Q, Rothman N, et al. Occupational trichloroethylene exposure and kidney cancer risk: a meta-analysis. Occup Environ Med. 2012;69:858-67.

Return to footnote240 referrer

Footnote 241

Lynch CF, Platz CE, Jones MP, Gazzaniga JM. Cancer registry problems in classifying invasive bladder cancer. J Natl Cancer Inst. 1991;83:429-33.

Return to footnote241 referrer

Footnote 242

Hankey BF, Edwards BK, Ries LA, Percy CL, Shambaugh E. Problems in cancer surveillance: Delineating in situ and invasive bladder cancer. J Natl Cancer Inst. 1991;83:384-5.

Return to footnote242 referrer

Footnote 243

Schned AR, Andrew AS, Marsit CJ, Zens MS, Kelsey KT, Karagas MR. Survival following the diagnosis of noninvasive bladder cancer: WHO/International Society of Urological Pathology versus WHO Classification systems. J Urol. 2007;178:1200.

Return to footnote243 referrer

Footnote 244

Brennan P, Bogillot O, Greiser E, et al. The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control. 2001;12:411-7.

Return to footnote244 referrer

Footnote 245

Zeegers MP, Tan FE, Dorant E, van den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiological studies. Cancer. 2000;89:630-9.

Return to footnote245 referrer

Footnote 246

Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311-22.

Return to footnote246 referrer

Footnote 247

Olfert SM, Felknor SA, Delclos GL. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. SouthMed J. 2006;99:1256-63.

Return to footnote247 referrer

Footnote 248

Letašiová S, Medvéová A, Šovèíková A. Bladder cancer, a review of the environmental risk factors. Environ Health. 2012;11 Suppl 1:S11.

Return to footnote248 referrer

Footnote 249

Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4-34.

Return to footnote249 referrer

Footnote 250

Siemiatycki J, Dewar R, Nadon L, Gérin M. Occupational risk factors for bladder cancer: results froma case-control study inMontreal, Quebec, Canada. Am J Epidemiol. 1994;140: 1061-80.

Return to footnote250 referrer

Footnote 251

Gaertner RR, Trpeski L, Johnson KC. A casecontrol study of occupational risk factors for bladder cancer in Canada. Cancer Causes Control. 2004;15:1007-19.

Return to footnote251 referrer

Footnote 252

Villanueva CM, Fernández F, Malats N, Grimalt JO, Kogevinas M. Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health. 2003;57:166-73.

Return to footnote252 referrer

Footnote 253

Villanueva CM, Cantor KP, King WD et al. Total and specific fluid consumption as determinants of bladder cancer risk. Int J Cancer. 2006;118:2040-7.

Return to footnote253 referrer

Footnote 254

Canadian Cancer Society's Steering Committee. Canadian cancer statistics 2009. Toronto: Canadian Cancer Society; 2009.

Return to footnote254 referrer

Footnote 255

Preston-Martin S, Munir R, Chakrabarti I. Nervous system. In: Cancer epidemiology and prevention, 3rd ed. Schottenfeld D, Fraumeni JF, editors. New York (NY): Oxford University Press; 2006. p. 1173-95.

Return to footnote255 referrer

Footnote 256

Hemminki K, Tretli S, Olsen JH, et al. Familial risks in nervous system tumours: joint Nordic study. Br J Cancer. 2010;102: 1786-90.

Return to footnote256 referrer

Footnote 257

Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009;20:525-31.

Return to footnote257 referrer

Footnote 258

Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973- 2002. JAMA. 2006;295:2164-7.

Return to footnote258 referrer

Footnote 259

Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784-91.

Return to footnote259 referrer

Footnote 260

Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177:1357-61.

Return to footnote260 referrer

Footnote 261

Cancer Care Ontario. Thyroid cancer incidence increasing in Ontario [Internet]. Toronto (ON): Cancer Care Ontario; 2010 [updated 2010 Mar 2; cited 2013 Oct 30].

Return to footnote261 referrer

Footnote 262

Ron E, Schneider AB. Thyroid Cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention, 3rd ed. New York (NY): Oxford University Press; 2006. p. 975-94.

Return to footnote262 referrer

Footnote 263

Haq M, Harmer C. Thyroid cancer: an overview. Nucl Med Commun. 2004;25:861-7.

Return to footnote263 referrer

Footnote 264

Zabel EW, Alexander BH, Mongin SJ, et al. Thyroid cancer and employment as a radiologic technologist. Int J Cancer. 2006;119:1940-5.

Return to footnote264 referrer

Footnote 265

Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141:259-77.

Return to footnote265 referrer

Footnote 266

Peterson E, De P, Nuttall R. BMI, diet and female reproductive factors as risks for thyroid cancer: a systematic review. PLoS ONE. 2012;7:e29177.

Return to footnote266 referrer

Footnote 267

Tsang RW, Hodgson DC, Crump M. Hodgkin's lymphoma. Curr Probl Cancer. 2006;30:107-58.

Return to footnote267 referrer

Footnote 268

Andersson J. Epstein-Barr virus and Hodgkin's lymphoma. Herpes. 2006;13:12-6.

Return to footnote268 referrer

Footnote 269

International Agency for Research on Cancer. Epstein-barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 70. Lyon, France, International Agency for Research on Cancer; 1997.

Return to footnote269 referrer

Footnote 270

Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a metaanalysis. Lancet. 2007;370:59-67.

Return to footnote270 referrer

Footnote 271

Goldin LR, Pfeiffer RM, Gridley G, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer. 2004;100:1902-8.

Return to footnote271 referrer

Footnote 272

Sergentanis TN, Kanavidis P, Michelakos T, Petridou ET. Cigarette smoking and risk of lymphoma in adults: a comprehensive metaanalysis on Hodgkin and non-Hodgkin disease. Eur J Cancer Prev. 2013;22:131-50.

Return to footnote272 referrer

Footnote 273

Kamper-Jørgensen M, Rostgaard K, Glaser SL, et al. Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Ann Oncol. 2013;24:2245-55.

Return to footnote273 referrer

Footnote 274

Chang ET, Zheng T, Weir EG, et al. Childhood social environment and Hodgkin's lymphoma: new findings from a populationbased case-control study. Cancer Epidemiol Biomarkers Prev. 2004;13:1361-70.

Return to footnote274 referrer

Footnote 275

Cancer Care Ontario. Cancer Fact: Hodgkin lymphoma incidence highest in young adults and elderly. Cancer Care Ontario; 2006 [updated 2009 Oct 21; cited 2013 Sept 6].

Return to footnote275 referrer

Footnote 276

Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109:3479-99.

Return to footnote276 referrer

Footnote 277

Crump C, Sundquist K, Sieh W, Winkleby MA, Sundquist J. Perinatal and family risk factors for non-Hodgkin lymphoma in early life: a Swedish National Cohort Study. J Natl Cancer Inst. 2012;104:923-30.

Return to footnote277 referrer

Footnote 278

Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16:405-8.

Return to footnote278 referrer

Footnote 279

Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004;95:745-52.

Return to footnote279 referrer

Footnote 280

Dal ML, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15:2078-85.

Return to footnote280 referrer

Footnote 281

Anderson LA, Engels EA. Hepatitis C virus infection and non-Hodgkin lymphoma: interesting association or causal relationship? Int J Cancer. 2008;122:10-2.

Return to footnote281 referrer

Footnote 282

Clarke CA, Glaser SL, Dorfman RF, Bracci PM, EberleE, HollyEA. Expert reviewof non- Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev. 2004;13(1):138-43.

Return to footnote282 referrer

Footnote 283

Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240-51.

Return to footnote283 referrer

Footnote 284

Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc. 2010;85:225-30.

Return to footnote284 referrer

Footnote 285

Renshaw C, Ketley N, Møller H, Davies EA. Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. BMC Cancer. 2010;10:74.

Return to footnote285 referrer

Footnote 286

Levi F, Te VC, Randimbison L, La Vecchia C. Incidence of multiple myeloma in Olmsted County, Minnesota. Cancer. 2005;104:442.

Return to footnote286 referrer

Footnote 287

Alexander DD, Mink PJ, Adami HO, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 2007;120 Suppl 12:40-61.

Return to footnote287 referrer

Footnote 288

Kristinsson SY, Goldin LR, Björkholm M, Koshiol J, Turesson I, Landgren O. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica. 2009;94:1581-9.

Return to footnote288 referrer

Footnote 289

Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-9.

Return to footnote289 referrer

Footnote 290

Larsson SC, Wolk A. Body mass index and risk of multiple myeloma: A meta-analysis. Int J Cancer. 2007;121:2512-6.

Return to footnote290 referrer

Footnote 291

Wallin A, Larson SC. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer. 2011;47:1606-15.

Return to footnote291 referrer

Footnote 292

Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52:611- 22.

Return to footnote292 referrer

Footnote 293

National Cancer Institute. SEER Stat Fact Sheets: Leukemia [Internet]. Bethesda (MD): National Cancer Institute; 2013 [updated 2013 Apr 1; cited 2013 Dec 19]. Available from:

Return to footnote293 referrer

Footnote 294

Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107:2099-107.

Return to footnote294 referrer

Footnote 295

International Agency for Research on Cancer. Classification of tumours. Pathology and genetics. Tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.

Return to footnote295 referrer

Footnote 296

Kasim K, Levallois P, Abdous B, Auger P, Johnson KC, Canadian Cancer Registries Epidemiology Research Group. Environmental tobacco smoke and risk of adult leukemia. Epidemiology. 2005;16:672-80.

Return to footnote296 referrer

Footnote 297

Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012;3:388.

Return to footnote297 referrer

Footnote 298

International Agency for Research on Cancer. Human immunodeficiency viruses and human T-cell lymphotropic viruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 67. Lyon (FR): IARC Press; 1996.

Return to footnote298 referrer

Footnote 299

Altieri A, Castro F, Bermejo JL, Hemminki K. Number of siblings and the risk of lymphoma, leukemia, and myeloma by histopathology. Cancer Epidemiol Biomarkers Prev. 2006;15:1281-6.

Return to footnote299 referrer

Footnote 300

Slager SL, Caporaso NE, de Sanjose S, Goldin LR. Genetic susceptibility to chronic lymphocytic leukemia. Semin Hematol. 2013;50:296-302.

Return to footnote300 referrer

Footnote 301

Goldin LR, Caporaso NE. Family studies in chronic lymphocytic leukaemia and other lymphoproliferative tumours. Br J Haematol. 2007;139:774-9.

Return to footnote301 referrer

Footnote 302

Crowther-Swanepoel D, Houlston RS. Genetic variation and risk of chronic lymphocytic leukaemia. Semin Cancer Biol. 2010;20:363-9.

Return to footnote302 referrer

Footnote 303

Ito T. Stem cell maintenance and disease progression in chronic myeloid leukemia. Int J Hematol. 2013;98:641-7.

Return to footnote303 referrer

Footnote 304

Liu-Dumlao T, Kantarjian H, Thomas DA, O'Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep. 2012;14:387- 94.

Return to footnote304 referrer

Footnote 305

Hoffbrand AV, Moss PAH, Pettit JE. Essential haematology, 5th ed. Oxford: Blackwell Publishing Ltd.; 2006.

Return to footnote305 referrer

Footnote 306

Taylor GM, Birch JM. The hereditary basis of human leukemia. In: Henderson ES, Lister TA, Greaves MJ, editors Leukemia, 6th ed. Philadelphia: WB Saunders; 1996. p. 210-45.

Return to footnote306 referrer

Footnote 307

Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010;15: 1083-101.

Return to footnote307 referrer

Footnote 308

Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: a metaanalysis of cohort studies. Int J Cancer. 2008;122:1418-21.

Return to footnote308 referrer

Footnote 309

Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol. 2004;159: 259-68.

Return to footnote309 referrer

Footnote 310

Kasim K, Johnson KC, Levallois P, Abdous B, Auger P, Canadian Cancer Registries Epidemiology Research Group. Recreational physical activity and the risk of adult leukemia in Canada. Cancer Causes Control. 2009;20:1377-86.

Return to footnote310 referrer

Footnote 311

Marrett LD, Ellison LF, Dryer D. Canadian cancer statistics at a glance: mesothelioma. CMAJ. 2008;178:677-8.

Return to footnote311 referrer

Footnote 312

American Cancer Society. Global Cancer Facts and Figures, 2nd Edition. Atlanta (GA): America Cancer Society; 2011 [cited 2013 Oct 30].

Return to footnote312 referrer

Footnote 313

International Agency for Research on Cancer. International Rules for Multiple Primary Cancers (ICD-O Third Edition) [Internet]. Lyon (FR): International Agency for Research on Cancer; 2004 [cited 2013 Oct 30].

Return to footnote313 referrer

Footnote 314

Quon H, Loblaw A, Nam R. Dramatic increase in prostate cancer cases by 2021. BJU Int. 2011;108:1734-8.

Return to footnote314 referrer

Page details

2019-06-11

Language selection

Search

References: Cancer incidence in Canada: trends and projections (1983-2032) - HPCDP: Volume 35, Supplement 1, Spring 2015

References

Page details